Immunocore Holdings plc

Immunocore Holdings plc

IMCR
Immunocore Holdings plcUS flagNASDAQ Global Select
32.39
USD
+2.55
- -
1.66BMarket Cap

Total Valuation

Immunocore Holdings plc carries a market capitalization of 1.66B, placing it among publicly traded companies globally. Its enterprise value stands at 787.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.66B
Enterprise Value787.48M

Share Statistics

Immunocore Holdings plc currently has 51.48M shares outstanding.

Shares Outstanding51.48M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.82, and the price-to-book ratio stands at 2.94.

PE RatioN/A
PS Ratio2.82
PB Ratio2.94
P/TBV Ratio2.94
P/FCF Ratio-42.62
P/OCF Ratio-34.69

Enterprise Valuation

EV / Sales1.83
EV / EBITDAN/A
EV / EBITN/A
EV / FCF14.25

Financial Position

Immunocore Holdings plc maintains a current ratio of 4.47, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 103.61, indicating elevated leverage, while an interest coverage ratio of -1.49 demonstrates limited ability to service its debt obligations.

Current Ratio4.47
Quick Ratio4.15
Debt / Equity103.61
Debt / EBITDA-22.93
Interest Coverage-1.49

Financial Efficiency

Return on Equity (ROE)-4.47
Return on Assets (ROA)-1.64
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)42.08
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.72

Taxes

Over the trailing twelve months, Immunocore Holdings plc has paid 15.34M in income taxes, reflecting an effective tax rate of 160.49.

Income Tax15.34M
Effective Tax Rate160.49

Stock Price Statistics

Immunocore Holdings plc's stock has declined approximately -4.56688% over the past 52 weeks. The 50-day moving average sits at 32.97, while the 200-day moving average is 31.82.

Beta (5Y)N/A
52-Week Price Change-4.56688%
50-Day Moving Average32.97
200-Day Moving Average31.82
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Immunocore Holdings plc generated 430.78M in revenue and converted that into -18.07M in net income, yielding earnings per share of -0.35. EBITDA reached -18.97M, while operating income came in at -22.58M.

Revenue430.78M
Gross Profit426.04M
Operating Income-22.58M
Pretax Income-2.73M
Net Income-18.07M
EBITDA-18.97M
EBIT-22.58M
Earnings Per Share (EPS)-0.35

Balance Sheet

Immunocore Holdings plc holds 880.21M in cash and equivalents against 434.96M in total debt, resulting in a net debt position of -90.71M. Total book value stands at 419.80M, with working capital of 815.85M providing operational flexibility.

Cash & Cash Equivalents880.21M
Total Debt434.96M
Net Debt-90.71M
Equity (Book Value)419.80M
Book Value Per Share8.15
Working Capital815.85M

Cash Flow

Immunocore Holdings plc produced -34.96M in operating cash flow over the past twelve months. After subtracting -6.19M in capital expenditures, free cash flow totaled -41.15M - equivalent to -0.81 per share.

Operating Cash Flow-34.96M
Capital Expenditures-6.19M
Free Cash Flow-41.15M
FCF Per Share-0.81

Margins

Immunocore Holdings plc operates with a gross margin of 98.90, reflecting its pricing power and cost economics. The operating margin of -5.24 and net profit margin of -4.20 provide insight into operational efficiency.

Gross Margin98.90
Operating Margin-5.24
Pretax Margin-0.63
Profit Margin-4.20
EBITDA Margin-4.40

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.89
FCF Yield-2.35

Scores

Immunocore Holdings plc posts an Altman Z-Score of 1.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.23